New Delhi: World Health Organisation (WHO) Officials had a meeting with those of Bharat Biotech and the Hyderabad-based vaccine maker’s dossier for Emergency Use Listing (EUL) of Covaxin is currently under review by the technical experts for consideration, WHO South-East Asia Regional Director Dr Poonam Khetrapal Singh said on Monday.
During her recent chat with ANI, Dr Singh also revealed that India has been offered 7.5 million doses of Moderna Covid vaccine through WHO’s COVID-19 Vaccines Global Access (COVAX) program.
The WHO Regional Director then went on to add, “Pfizer, AstraZeneca, Moderna, Johnson and Johnson, Sinovac and Sinopharm have been granted EUL by the WHO. For COVXIN, an expression of interest for EUL has been made to WHO by Bharat Biotech. WHO has already conducted a pre-submission meeting with the company following which a dossier has been submitted by Bharat Biotech to WHO in early July. The dossier is currently under review by the technical experts for consideration of EUL.”
Expressing her thoughts over the possibility of the COVID-19 Delta variant becoming the most dominant strain, Dr Singh said, “Delta variant has spread to over 100 countries, the way its spreading is likely to soon become the most dominant COVID strain globally.”
“Among all variants of concern, Delta spreads most rapidly. The rapid spread means more cases, leading to more pressure on health systems and more deaths,” she added.
The WHO South-East Asia director further said that COVID-19 cases and fatalities were again increasing on the global stage.
“The more we allow the virus to spread, the more it will evolve, resulting in more variants. We need to ensure that public health and social measures are implemented continuously. The interventions proven to be effective even against the delta variant,” she said.